Last $2.70 USD
Change Today +0.05 / 1.89%
Volume 970.7K
ATRS On Other Exchanges
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $4.60
52 Week Low
09/30/14 - $1.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; Meda Pharmaceuticals; Pfizer Inc; Population Council; and LEO Pharma. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

60 Employees
Last Reported Date: 03/13/14
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2013.

antares pharma inc (ATRS) Key Developments

Antares Pharma Announces Positive Top-Line Pharmacokinetic Results from the QuickShot® Phase 3 Study in Testosterone Deficient Men

Antares Pharma Inc. announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company’s ongoing, multi-center, phase 3 clinical study (QST-13-003) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot® auto injector in testosterone deficient adult males. In the study, 150 adult males with hypogonadism (low testosterone) and testosterone blood levels less than 300 ng/dL received a starting dose of 75 mg of subcutaneously administered testosterone enanthate (QuickShot® Testosterone, or QS T) once weekly for six weeks. Blinded adjustments to dose were made when necessary at week seven based upon the week six pre-dose blood level, and full pharmacokinetic (PK) profiles were obtained during the 12th week of treatment. The protocol for the study required that at the week 12 endpoint: (i) at least 75% of all patients’ Cavg are within the normal range of 300 to 1100 ng/dL, with a lower limit of a 95% 2-sided confidence interval of greater than or equal to 65%, (ii) at least 85% of patients’ Cmax are less than 1500 ng/dL and (iii) no more than 5% of patients had a Cmax greater than 1800 ng/dL. The primary endpoint of the population that received one or more doses of QS T was met by 139 out of 150 patients, equating to 92.7% with a 95% confidence interval of 87.3% to 96.3%. Among the 137 patients that completed all 12 weeks of dosing and PK sampling, 98.5% were within the pre-defined range.

Antares Pharma Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 04:05 PM

Antares Pharma Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 04:05 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Eamonn P. Hobbs, Chief Executive Officer, President, Director, Member of Audit Committee and Member of Governance & Nominating Committee.

Antares Pharma Provides Regulatory Update on Sumatriptan Injection USP

Antares Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the FDA provided revisions to labelling and cited minor deficiencies. If approved, Sumatriptan Injection USP would represent the Companys first ANDA approval and second device approved from the VIBEX® auto injector platform. As previously disclosed, Teva Pharmaceutical Industries Ltd. would distribute the product and share the profits equally with Antares Pharma.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.70 USD +0.05

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerus Corp $4.46 USD +0.02
Cytori Therapeutics Inc $1.14 USD -0.06
Pluristem Therapeutics Inc $3.23 USD +0.14
STAAR Surgical Co $7.31 USD -0.45
SurModics Inc $24.34 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at